Ticker Details
Adverum Biotechnologies, Inc. Adverum Biotechnologies Inc is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye.
IPO Date:	May 12, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$96.26M
Activated in VL:	False

Average Daily Range
Avg Daily Range:	$0.20 | 3.64%
Avg Daily Range (30 D):	$0.13 | 3.07%
Avg Daily Range (90 D):	$0.16 | 3.70%

Institutional Daily Volume
Avg Daily Volume:	.71M
Avg Daily Volume (30 D):	M
Avg Daily Volume (90 D):	.45M

Trade Size
Avg Trade Size (Sh.):	171
Avg Trade Size (Sh.) (30 D):	190
Avg Trade Size (Sh.) (90 D):	141

Institutional Trades
Total Institutional Trades:	1,059
Avg Institutional Trade:	$1.82M
Avg Institutional Trade (30 D):	$.88M
Avg Institutional Trade (90 D):	$.88M
Avg Institutional Trade Volume:	.04M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.18M
Avg Closing Trade (30 D):	$4.03M
Avg Closing Trade (90 D):	$4.03M
Avg Closing Volume:	33.19K

News

Nov 19, 2025 @ 12:15 AM Halper Sadeh LLC Encourages CMA, ADVM, HOUS Shareh... Source: Halper Sadeh Llc

Nov 5, 2025 @ 6:00 PM Choroidal Neovascularization Market to Witness Acc... Source: Delveinsight

Oct 24, 2025 @ 6:57 PM Halper Sadeh LLC Encourages ADVM, MOFG, HSII Share... Source: Halper Sadeh Llc

Oct 24, 2025 @ 3:14 PM Eli Lilly Bets Big On Eye Gene Therapy That Could ... Source: Triveni Kothapalli

Aug 18, 2025 @ 2:00 PM Global Ophthalmology Drugs Market to Reach USD 26.... Source: Marketsandmarkets

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$-2.03	$-2.34	$-2.25
Diluted EPS	$-2.03	$-2.34	$-2.25
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-47.65M	$-49.19M	$-47.02M
Operating Income / Loss	$-48.02M	$-49.86M	$-48.22M
Cost of Revenue
Net Cash Flow	$-16.36M	$-18.23M	$M
PE Ratio